
Publisher's PDF, also known as Version of record

License (if available): Other

Link to published version (if available): 10.1002/ajmg.a.40484

Link to publication record in Explore Bristol Research

PDF-document

This is the final published version of the article (version of record). It first appeared online via Wiley at https://onlinelibrary.wiley.com/doi/full/10.1002/ajmg.a.40484. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms
**NEW SYNDROME**

**TRPV6 compound heterozygous variants result in impaired placental calcium transport and severe undermineralization and dysplasia of the fetal skeleton**

Christine P. Burren¹,² | Richard Caswell³ | Bruce Castle⁴ | C. Ross Welch⁵ | Tom N. Hilliard⁶ | Sarah F. Smithson²,⁷ | Sian Ellard³,⁸

¹Department of Paediatric Endocrinology, Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
²Bristol Medical School Translational Health Sciences, University of Bristol, Bristol, United Kingdom
³Institute of Biomedical and Clinical Science, University of Exeter, Exeter, United Kingdom
⁴Department of Clinical Genetics, Royal Devon & Exeter Hospital, Exeter, United Kingdom
⁵Department of Fetomaternal Medicine, Derriford Hospital, Plymouth, United Kingdom
⁶Department of Paediatric Respiratory Medicine, Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
⁷Department of Clinical Genetics, St Michaels Hospital, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
⁸Department of Molecular Genetics, Royal Devon & Exeter Hospital, Exeter, United Kingdom

**Correspondence**
Christine Pamela Burren, Department of Paediatric Endocrinology, Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Upper Maudlin St, Bristol BS2 8BJ, UK.
Email: christine.burren@uhbristol.nhs.uk

**Funding information**
Wellcome Trust, Grant/Award Number: Senior Investigator Award 098395/Z/12/A

**Transient receptor potential vanilloid 6 (TRPV6) functions in tetramer form for calcium transport. Until now, TRPV6 has not been linked with skeletal development disorders. An infant with antenatal onset thoracic insufficiency required significant ventilatory support. Skeletal survey showed generalized marked undermineralization, hypoplastic fractured ribs, metaphyseal fractures, and extensive periosteal reaction along femoral, tibial, and humeral diaphyses. Parathyroid hormone (PTH) elevation (53.4–101 pmol/L) initially suggested PTH signaling disorders. Progressively, biochemical normalization with radiological mineralization suggested recovery from in utero pathophysiology. Genomic testing was undertaken and in silico protein modeling of variants. No abnormalities in antenatal CGH array or UPD14 testing. Postnatal molecular genetic analysis found no causative variants in CASR, GNA11, APS21, or a 336 gene skeletal dysplasia panel investigated by whole exome sequencing. Trio exome analysis identified compound heterozygous TRPV6 likely pathogenic variants: novel maternally inherited missense variant, c.1978G > C p.(Gly660Arg), and paternally inherited nonsense variant, c.1528C > T p.(Arg510Ter), confirming recessive inheritance. p.(Gly660Arg) generates a large side chain protruding from the C-terminal hook into the interface with the adjacent TRPV6 subunit. In silico protein modeling suggests steric clashes between interface residues, decreased C-terminal hook, and TRPV6 tetramer stability. The p.(Gly660Arg) variant is predicted to result in profound loss of TRPV6 activity. This first case of a novel dysplasia features severe but improving perinatal abnormalities. The TRPV6 compound heterozygous variants appear likely to interfere with fetoplacental calcium transfer crucial for in utero skeletal development. Astute clinical interpretation of evolving perinatal abnormalities remains valuable in complex calcium and bone pathophysiology and informs exome sequencing interpretation.**

**KEYWORDS**
hyperparathyroidism, placental calcium transfer, skeletal demineralization, TRPV6 (transient receptor potential channel 6), skeletal dysplasia

**1 | INTRODUCTION**

Recent advances in molecular genetics have facilitated an expansion and refinement of skeletal dysplasias and metabolic bone conditions diagnosed perinatally (Bonafe et al., 2015).
TRPV6 is relevant to calcium absorption (Fecher-Trost, Wissenbach, & Weissgerber, 2017). TRPV6 gene location and expression varies across species; in humans, TRPV6 is situated on chromosome 7q33-q34 and is expressed in prostate, placenta, epididymis, and exocrine pancreas (Wissenbach et al., 2001). Research has focused on the potential contribution of TRPV6 overexpression in prostate and breast cancer. Fewer reports address underexpression: the trpv6−/− knockout mouse has hypofertility due to altered calcium homeostasis in the epididymis and in humans reduced placental expression is associated with preeclampsia (Haché et al., 2011). Until now, TRPV6 has not been linked with disorders of bone mineralization or skeletal dysplasia. We describe a patient with this phenotype and compound heterozygote TRPV6 variants occurring in trans, illustrating how astute clinical interpretation of evolving perinatal calcium and bone pathophysiology informed the interpretation of trio exome sequencing.

2 | CASE

A term female infant required significant and prolonged ventilatory support from birth due to severe thoracic insufficiency, accompanied by skeletal and biochemical abnormalities. Management included difficult discussions around survival. Therefore, identifying the underlying diagnosis in this neonate with rare bone disease was invaluable to better inform prognosis.

Antenatal abnormalities were noted early in pregnancy on the 20/40 gestation scan: small chest, unusual rib configuration, short but straight long bones, and no fractures identified. Pregnancy was complicated by severe and reaccumulating polyhydramnios which required three amniotic fluid drainage procedures from 27/40 gestation. There was no preeclampsia. Parents were counseled regarding the severe phenotype of the potentially lethal skeletal dysplasia, with no clear diagnosis.

Elective induction of labor at 39 1/40, emergency cesarean section delivery due to fetal distress, birth weight 3.6 kg, Apgars 3 1, 6, 8, 10, and endotracheal intubation and ventilation were required in the delivery room. Clinical features included a marked bell-shaped chest, otherwise normal proportions, no dysmorphic features and neurologically normal (Figure 1a). Ventilatory requirement persisted; trial of extubation failed Days 4 and 15 and conventional mechanical ventilation was required with maximum pressures of 30 cm H2O and FiO2 0.6. Morphine infusion and paralysis were required for pain attributed to underlying fractures.

The skeletal survey showed widespread undermineralization, short, fractured ribs, metaphyseal irregularities with corner fractures, and periosteal reaction along diaphyses of the long bones (Figure 1b–i).

Early biochemical abnormalities featured markedly elevated PTH 53.4 rising to 101 pmol/L (normal 1.1–6.9 pmol/L), normocalcemia
corrected calcium 2.43 mmol/L, normophosphatemia 1.4 mmol/L, normal Alkaline Phosphatase (ALP) 289 IU/L, normal urinary calcium/creatinine ratio 1.05, and vitamin D insufficiency 29 nmol/L. Parental biochemistry was normal.

Neonatal severe hyperparathyroidism (NSHPT) was considered, based on marked PTH elevation and periosteal abnormalities, despite the absence of hypercalcemia; pamidronate single dose Day 16 then daily cinacalcet (calcimimetic) were used preemptively to avoid anticipated severe hypercalcemia (Fisher, Cabrera, & Imel, 2015). PTH normalized, serum calcium did not rise, including after cinacalcet cessation. Transient mild hypocalcemia and hypophosphatemia occurred at weeks 3–4.

At the age of 6 weeks, X-rays showed improved rib mineralization and width and there was partial resolution of long bone periosteal abnormalities (Figure 1j,k). Ongoing metabolic bone strategy was oral calcium provision as substrate to facilitate bone mineralization and routine vitamin D supplementation (400 IU/day). The ventilatory requirement remained significant but sufficiently improved, with a decision to commence long-term ventilation through a tracheostomy from 8 weeks.

Throughout 2–4 months of age, skeletal mineralization improved and ventilation stabilized on bi-level pressures of 16/6 without additional oxygen. Developmental progress was normal. There was a degree of feed volume intolerance attributed to thorax and abdomen size and no other abnormalities identified. Preparation commenced toward transfer and home ventilation, envisaged for approximately 12 months.

Unexpectedly at 4 months, she developed sudden and marked abdominal distension followed by cardiac arrest, profound, and prolonged lactic acidosis. Emergency laparotomy identified volvulus and ischemic bowel. Neurological status postarrest was extremely poor, Magnetic Resonance Imaging (MRI) brain demonstrated global ischemic injury and ultimately care was withdrawn. Limited postmortem exploration of the candidate genes (PanelApp skeletal dysplasia panel Version 1.66, which includes 336 “green” genes (PanelApp skeletal dysplasia panel version 1.66, 2016). No likely causative variants were found through these gene-focused approaches, excluding a diagnosis of a known form of skeletal dysplasia.

This extensive negative genetic testing, alongside postnatal clinical, biochemical, and radiological changes prompted revision of the intrinsic PTH abnormality hypothesis. Normalized PTH and progressively improved skeletal mineralization suggested the PTH elevation had been reactive to in utero calcium deficiency which progressively resolved in the postnatal environment. The in utero calcium deficiency was not felt to be due to maternal factors (normal biochemistry, health and pregnancy vitamin supplementation). Instead, an intrinsic defect in placental calcium transfer was postulated, prompting direct exploration of the candidate genes TRPV6, C6BP9K, and VDR. We sequenced the unaffected parents and performed a gene-agnostic trio analysis to identify very rare variants (MAF < 0.0001) compatible with autosomal recessive or de novo inheritance. This identified two genes with possible compound heterozygous single nucleotide variants (SNVs) or indels and one gene with a de novo variant. These included compound heterozygous TRPV6 variants (NM_018646.5); a novel missense variant, p.(Gly660Arg), and a rare nonsense variant, p.(Arg510Ter) classified according to the ACMG guidelines (Richards et al., 2015) as likely pathogenic (missense: PM2_moderate, PM3_moderate, PP3_supporting, PP4_supporting and nonsense: PV51_very strong, PM2_moderate). The p.(Arg510Ter) variant lies in exon 11 of 15, and is assumed to induce nonsense-mediated decay. Glycine 660 lies within the C-terminal hook region in the intracellular “skirt” of TRPV6 (Saotome, Singh, Yelshanskaya, & Sobolevsky, 2016). The C-terminal hook packs against the N-terminal helix of the neighboring subunit, forming an interface at each corner of the skirt (Figure 2a,b). To analyses the effect of the p.(Gly660Arg) substitution, in silico mutagenesis was performed using the Fold X modeling suite (Schymkowitz et al., 2005) to introduce the variant into recently published structures of TRPV6 in its open and closed forms (PDB identifiers 6bo8 and
In the predicted structure of the open form of the variant protein, the novel arginine side chain protrudes into the interface between the C-terminal hook and the N-terminal helix of the neighboring subunit, resulting in displacement of a number of side chains which contribute both to the interface and the stability of the loop forming the C-terminal hook (Figure 2c,d). The p.(Gly660Arg) variant also resulted in steric clashes between residues at the interface, and similar observations were made for the closed form of the tetramer (data not shown). The structure of the hook is likely stabilized by a hydrophobic core formed by nonpolar side chains, particularly Leu665, Ile658, and Phe670; the introduction of the large, basic arginine side chain disrupts this environment (Figure 3) and is expected to be energetically unfavorable. Indeed, thermodynamic analysis of the tetramer using FoldX indicated an increase in free energy (>3 kcal/mol) are generally regarded as highly destabilizing to protein structure (Tokuriki & Tawfik, 2009), suggesting that the p. (Gly660Arg) substitution is likely to cause loss of stability at the oligomerization interface and/or reduced formation of the functional tetramer. This may also lead to reduced levels of TRPV6 protein as a result of increased turnover of unstable or misfolded protein. Thus, in combination with the p.(Arg510Ter) allele, the p.(Gly660Arg) variant is predicted to result in a profound loss of TRPV6 activity.

**FIGURE 2** Location of Gly660 and effect of p.(Gly660Arg) substitution. (a) Structure of the human TRPV6 tetramer in open form (PDB id 6bo8); chains A–D are colored cyan, yellow, gray, and pink respectively; atoms of Gly660 are shown in all subunits as spheres colored by atom type (white, carbon; blue, nitrogen; red, oxygen), and are labeled for subunits A and D. The complex is oriented to show view in the plane of the membrane, represented by the gray bar, with the cytoplasmic region at the top. (b) As A, but rotated to show the view from the cytoplasm; the ion channel lies at the center of the tetramer. (c) Detail of the interface between the C-terminal hook of subunit A (cyan) and the N-terminal helix of subunit B (yellow); the position of the Gly660 backbone is indicated, and side chains shown in stick format, colored by atom type, for other relevant residues; residues from subunits A and B are labeled in black or blue font, respectively. (d) As A, but showing detail of the p.(Gly660Arg) variant. Variant details: missense is c.1978G > C and nonsense is c.1528C > T. Genomic coordinates Chr7(GRCh37):g.142570162C > G and Chr7(GRCh37):g.142572288G > A) [Color figure can be viewed at wileyonlinelibrary.com]
mineralization causing life-threatening thoracic insufficiency and morbidity from postnatal fractures. Initial differential diagnoses to consider include skeletal dysplasias characterized by poor skeletal mineralization including osteogenesis imperfecta, hypophosphatasia, mucolipidosis Type II, and NSHPT. The unusual clues in this case were in the initial biochemical abnormalities, generally absent in skeletal dysplasias, and their progressive postnatal resolution and bone healing away from the in utero environment.

Finding the precise diagnosis in the patient was fundamental to inform clinical decisions. A hypothesis driven approach to genetic tests contributed first in excluding an unusual presentation of a rare disease (some features suggested NSHPT but severity causing antenatal abnormalities has not been reported) and ongoing hypothesis development complemented a gene-agnostic trio exome sequence analysis.

Identification of compound heterozygous TRPV6 variants in this patient coincides with new information on how TRPV6 operates for calcium transfer. TRPV6 crystal structure has been recently described (McGoldrick et al., 2017; Saotome et al., 2016). The gene changes in our patient lie at the tetrameric interface crucial for calcium channel function (McGoldrick et al., 2017) and are predicted to destabilize the protein complex resulting in loss of calcium transport.

Although trpv6 is expressed in many mouse tissues, including intestine, expression in humans appears restricted to placenta, exocrine pancreas, and some exocrine glands (Fecher-Trost et al., 2017). Our case showed effects of compromised placental calcium transfer, but did not demonstrate any exocrine pancreatic dysfunction features such as intestinal malabsorption. The absence of preeclampsia does not reinforce the hypothesis of TRPV6 dysfunction in preeclampsia (Haché et al., 2011). Our case showed normal intestinal calcium transfer during early infancy; although oral calcium supplementation was briefly required to compensate for skeletal calcium deficiency, ongoing normal milk calcium content achieved normocalcemia.

The TRPV gene family has previously been implicated in skeletal dysplasia: mutations in the TRPV4 gene are associated with skeletal dysplasia, arthritis-like, and neurological phenotypes including spondyloepiphyseal dysplasia Kozlowski type, brachyholmia Type 3, metatropic dysplasia, spondyloepiphyseal dysplasia Maroteaux type, familial digital arthropathy-brachydactyly, Charcot–Marie–Tooth disease Type 2C, congenital distal spinal muscular atrophy, and scapuloperoneal spinal muscular atrophy (Krakow et al., 2009; Lamandé et al., 2014; Zimoi et al., 2010). Severe perinatal skeletal dysplasia has not been reported in association with TRPV6. Our case has intriguing similarities to severe antenatal-onset Caffey disease including polyhydramnios, hyperostosis, periosteal reaction, and progressive resolution of bony lesions over time (Schweiger et al., 2003), although we did not observe soft tissue swellings or fever. Antenatal Caffey disease is very rare and although heterozygote COL1A1 mutations have been identified in some cases (Gensure et al., 2005), genetic heterogeneity seems likely and TRPV6 may be a candidate worth investigation in unsolved cases.

Combined clinical and genetic expertise achieved diagnostic precision for this case and contributes to understanding of TRPV6 in human disease.

ACKNOWLEDGMENTS
The authors gratefully acknowledge the kind permission of the family to publish this case. The authors would like to thank clinical and radiological colleagues who contributed to case discussion. The trio exome sequence bioinformatics analysis pipeline was provided by Dr. Matthew Wakeling. The authors would also like to thank Andrew Parrish and Dr. Julia Baptista for their assistance with the exome sequencing data analysis. S.E. holds Wellcome Trust Senior Investigator Award 098395/Z/12/A.

CONFLICT OF INTEREST
The authors declared that they have no conflict of interest.

AUTHOR CONTRIBUTIONS
CB: Clinical care of patient including management of calcium homeostasis, recognition of candidate genes for phenotype, main author of this manuscript.
RC: In silico work, analysis of protein structure and consequences of variants in TRPV6, construction of Figure 2, contributor to this manuscript.

BC: Clinical care including antenatal genetic investigation, contributor to this manuscript.

CRW: Clinical care antenatally, approval of final manuscript.

TNH: Clinical care of patient focusing on respiratory management, contributor to this manuscript.

SS: Contribution to phenotypic analysis, interpretation of genetic data and to writing this manuscript.

SE: Scientific design of trio exome sequence analysis, interpretation of genetic data and contributor to this manuscript.

ORCID
Christine P. Burren http://orcid.org/0000-0002-3778-2945

REFERENCES


